MELISSA KORZI: Open Payments
NPI 1508907049 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,525 in 36 payments from 12 companies in 2025. Trend: 2023 $1,645 · 2024 $1,432 · 2025 $1,525
Food & beverage: $1,525
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $309 |
| AstraZeneca Pharmaceuticals LP | 2 | $161 |
| Lilly USA, LLC | 6 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $147 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Novo Nordisk Inc | 1 | $114 |
| Axsome Therapeutics, Inc. | 1 | $114 |
| Verona Pharma, Inc. | 1 | $103 |
| SHIELD THERAPEUTICS INC | 3 | $73 |
Products named: VRAYLAR, CAPLYTA, Kerendia, VOQUEZNA, ZEPBOUND, AIRSUPRA, Wegovy, Symbravo.
Industry payments across PA — which companies pay providers there.
